Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/239970
COMPARTIR / EXPORTAR:
SHARE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper |
Autor: | Los-Arcos, Ibai; Iacoboni, Gloria; Aguilar Guisado, Manuela CSIC ORCID; Alsina, Laia; Díaz de Heredia, Cristina; Fortuny, Claudia; García-Cadenas, Irene; García‐Vidal, Carolina; González-Vicent, Marta; Hernani, Rafael; Kwon, Mi; Machado, Marina; Martínez-Gómez, Xavier; Ortiz-Maldonado, Valentín; Pinto Pla, Carolina; Piñana, José Luis; Pomar, Virginia; Reguera-Ortega, Juan Luis; Salavert, Miguel; Soler-Palacín, Pere; Vázquez-López, Lourdes; Barba, Pere; Ruiz-Camps, Isabel | Palabras clave: | Chimeric antigen receptor Diffuse large B-cell lymphoma B-cell acute lymphoblastic leukemia Bacterial infections Viral infections Fungal infections |
Fecha de publicación: | abr-2021 | Editor: | Springer Nature | Citación: | Infection 49: 215-231 (2021) | Resumen: | Chimeric antigen receptor (CAR) T-cell therapy is one of the most promising emerging treatments for B-cell malignancies. Recently, two CAR T-cell products (axicabtagene ciloleucel and tisagenlecleucel) have been approved for patients with aggressive B-cell lymphoma and acute lymphoblastic leukemia; many other CAR-T constructs are in research for both hematological and non-hematological diseases. Most of the patients receiving CAR-T therapy will develop fever at some point after infusion, mainly due to cytokine release syndrome (CRS). The onset of CRS is often indistinguishable from an infection, which makes management of these patients challenging. In addition to the lymphodepleting chemotherapy and CAR T cells, the treatment of complications with corticosteroids and/or tocilizumab increases the risk of infection in these patients. Data regarding incidence, risk factors and prevention of infections in patients receiving CAR-T cell therapy are scarce. To assist in patient care, a multidisciplinary team from hospitals designated by the Spanish Ministry of Health to perform CAR-T therapy prepared these recommendations. We reviewed the literature on the incidence, risk factors, and management of infections in adult and pediatric patients receiving CAR-T cell treatment. Recommendations cover different areas: monitoring and treatment of hypogammaglobulinemia, prevention, prophylaxis, and management of bacterial, viral, and fungal infections as well as vaccination prior and after CAR-T cell therapy. | Versión del editor: | http://doi.org/10.1007/s15010-020-01521-5 | URI: | http://hdl.handle.net/10261/239970 | DOI: | 10.1007/s15010-020-01521-5 | Identificadores: | doi: 10.1007/s15010-020-01521-5 issn: 0300-8126 e-issn: 1439-0973 |
Aparece en las colecciones: | (IBIS) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 15,38 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
33
checked on 11-abr-2024
Page view(s)
108
checked on 01-may-2024
Download(s)
22
checked on 01-may-2024
Google ScholarTM
Check
Altmetric
Altmetric
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.